stockrow
Friday 6 November 2026
Export VCEL’s income statement to Excel — free account
Vericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
54.47
2.69
+5.20%
Follow VCEL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
112.53 | 74.81 | 92.69 | 60.82 |
P/S ratio |
6.56 | 5.59 | 7.42 | 6.34 | |
P/FCF ratio |
73.25 | 34.40 | 36.85 | 35.49 | |
P/Operating CF |
120.74 | 99.70 | 140.35 | 115.93 | |
P/B ratio |
5.11 | 4.59 | 6.14 | 5.35 | |
Price to Tangible BV |
5.19 | 4.66 | 6.23 | 5.42 | |
EV/Sales |
6.13 | 5.15 | 6.94 | 5.87 | |
EV/EBITDA |
74.82 | 53.72 | 68.01 | 60.80 | |
EV/Operating CF |
32.61 | 24.40 | 30.53 | 29.12 | |
EV/FCF |
68.39 | 31.70 | 34.50 | 32.85 | |
Quick Ratio |
4.52 | 4.62 | 4.53 | 4.61 | |
Current Ratio |
5.03 | 5.18 | 5.04 | 5.13 | |
Net Debt/EBITDA |
(5.37) | 30.47 | (40.05) | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.60 | 0.64 | 0.65 | 0.67 | |
Operating CF/Net income |
0.65 | (2.60) | 7.34 | 1.25 | |
Capex/Depreciation |
(0.68) | (0.38) | (0.53) | 0.00 | |
Interest Coverage |
138.36 | (50.40) | 2.71 | 76.16 | |
Research and Development Expense of Revenue |
7.81% | 11.84% | 9.67% | 8.06% | |
Selling, General and Administrative Expense of Revenue |
46.77% | 71.94% | 62.58% | 51.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
9.06% | 16.51% | 11.73% | 9.16% | |
Graham Net Nets |
0.06 | 0.07 | 0.06 | 0.07 | |
Graham Number |
7.12 | 8.24 | 8.85 | 10.56 | |
Earnings Yield |
0.89% | 1.34% | 1.08% | 1.64% | |
Free Cash Flow Yield |
1.37% | 2.91% | 2.71% | 2.82% | |
Revenue per Share |
1.85 | 1.35 | 1.52 | 1.67 | |
Operating CF per Share |
0.30 | 0.32 | 0.32 | 0.35 | |
Capex per Share |
(0.04) | (0.02) | (0.04) | (0.04) | |
Free Cash Flow per Share |
0.25 | 0.30 | 0.28 | 0.31 | |
Cash per Share |
2.73 | 2.86 | 3.18 | 3.33 | |
Shareholders Equity per Share |
7.04 | 7.02 | 7.25 | 7.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.04 | 7.02 | 7.25 | 7.51 | |
Free Cash Flow |
12.83 | 15.13 | 14.26 | 15.68 | |
Working Capital |
198.29 | 196.91 | 212.20 | 226.05 | |
Capital Expenditures |
(2.19) | (1.26) | (1.93) | (2.04) | |
Net Current Asset Value |
114.11 | 114.67 | 131.91 | 147.83 | |
EV/EBIT |
153.25 | 95.44 | 116.65 | 70.51 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
164.14 | 103.56 | 124.61 | 76.18 | |
| Other line items | |||||
Average Receivables |
73.00 | 62.64 | 70.00 | 71.11 | |
Average Payables |
19.84 | 17.88 | 16.74 | 17.65 | |
Average Inventory |
17.47 | 17.73 | 17.61 | 17.61 | |
Average Assets |
460.35 | 455.11 | 469.24 | 485.19 | |
Average Common Equity |
323.30 | 325.86 | 338.43 | 353.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026